Stephens & Co. downgrades NeoGenomics (NASDAQ:NEO) from Overweight to Equal-Weight and lowers the price target from $34 to $16.
Annexon’s Interim Mid-Stage Results On Huntington’s Disease Candidate Fails To Cheer
Annexon Inc (NASDAQ: ANNX)
Stephens & Co. Downgrades NeoGenomics to Equal-Weight, Lowers Price Target to $16
Stephens & Co. downgrades NeoGenomics (NASDAQ:NEO) from Overweight to Equal-Weight and lowers the price target from $34 to $16.
Related Posts
Floki Inu Promises ‘To Go Mainstream In Nigeria’
Floki Inu (CRYPTO: FLOKI) — a memecoin challenging the dominance of Dogecoin (CRYPTO: DOGE) and Shiba Inu (CRYPTO: SHIB) &md
GE Chief Larry Culp Agrees To $10M Pay Cut This Year, Keeps Job Until 2024 After Shareholder Concerns
General Electric Co (NYSE: GE) said on Thursday CEO Larry Culp has agreed to lower his annual compensation by $10 million and retained his contract until 2024 in response to shareholder concerns last year.
MariMed Appoints Jon Levine As President
MariMed, Inc. (CSE:MRMD), (OTCQX: MRMD) appointed Jon Levine as president.